426 related articles for article (PubMed ID: 28447565)
1. Risk factors for brain metastases in patients with metastatic colorectal cancer.
Christensen TD; Palshof JA; Larsen FO; Høgdall E; Poulsen TS; Pfeiffer P; Jensen BV; Yilmaz MK; Christensen IJ; Nielsen D
Acta Oncol; 2017 May; 56(5):639-645. PubMed ID: 28447565
[TBL] [Abstract][Full Text] [Related]
2. Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer.
Christensen TD; Palshof JA; Larsen FO; Poulsen TS; Høgdall E; Pfeiffer P; Jensen BV; Yilmaz MK; Nielsen D
Acta Oncol; 2018 Aug; 57(8):1057-1062. PubMed ID: 29380640
[TBL] [Abstract][Full Text] [Related]
3. The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern.
Prasanna T; Karapetis CS; Roder D; Tie J; Padbury R; Price T; Wong R; Shapiro J; Nott L; Lee M; Chua YJ; Craft P; Piantadosi C; Sorich M; Gibbs P; Yip D
Acta Oncol; 2018 Nov; 57(11):1438-1444. PubMed ID: 30035653
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
[TBL] [Abstract][Full Text] [Related]
5. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer.
Morris V; Overman MJ; Jiang ZQ; Garrett C; Agarwal S; Eng C; Kee B; Fogelman D; Dasari A; Wolff R; Maru D; Kopetz S
Clin Colorectal Cancer; 2014 Sep; 13(3):164-71. PubMed ID: 25069797
[TBL] [Abstract][Full Text] [Related]
6. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
[TBL] [Abstract][Full Text] [Related]
7. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain.
Feliu J; Díez de Corcuera I; Manzano JL; Valladares-Ayerbes M; Alcaide J; García García T; Vera R; Sastre J
Clin Transl Oncol; 2017 Apr; 19(4):498-507. PubMed ID: 27718155
[TBL] [Abstract][Full Text] [Related]
9. Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.
Sasaki Y; Hamaguchi T; Yamada Y; Takahashi N; Shoji H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Nagai Y; Taniguchi H; Boku N; Ushijima T; Shimada Y
Asian Pac J Cancer Prev; 2016; 17(2):539-43. PubMed ID: 26925640
[TBL] [Abstract][Full Text] [Related]
10. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
[TBL] [Abstract][Full Text] [Related]
11. Impact of Metastasectomy in the Multimodality Approach for
Johnson B; Jin Z; Truty MJ; Smoot RL; Nagorney DM; Kendrick ML; Kipp BR; Grothey A
Oncologist; 2018 Jan; 23(1):128-134. PubMed ID: 28904173
[TBL] [Abstract][Full Text] [Related]
12. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
[TBL] [Abstract][Full Text] [Related]
13. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases.
Fujiyoshi K; Yamamoto G; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
Oncol Rep; 2017 Feb; 37(2):785-792. PubMed ID: 28000889
[TBL] [Abstract][Full Text] [Related]
14. KRAS Status as a Predictor of Chemotherapy Activity in Patients With Metastatic Colorectal Cancer.
Yarom N; Gresham G; Boame N; Jonker D
Clin Colorectal Cancer; 2019 Dec; 18(4):e309-e315. PubMed ID: 31547963
[TBL] [Abstract][Full Text] [Related]
15. Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy.
Manceau G; Imbeaud S; Thiébaut R; Liébaert F; Fontaine K; Rousseau F; Génin B; Le Corre D; Didelot A; Vincent M; Bachet JB; Chibaudel B; Bouché O; Landi B; Bibeau F; Leroy K; Penault-Llorca F; Van Laethem JL; Demetter P; Tejpar S; Rossi S; Mosakhani N; Osterlund P; Ristamäki R; Sarhadi V; Knuutila S; Boige V; André T; Laurent-Puig P
Clin Cancer Res; 2014 Jun; 20(12):3338-47. PubMed ID: 24771647
[TBL] [Abstract][Full Text] [Related]
16. Metastatic colo-rectal cancer: real life experience from an Indian tertiary care center.
Sharma V; Sharma A; Raina V; Dabkara D; Mohanti BK; Shukla NK; Pathy S; Thulkar S; Deo SVS; Kumar S; Sahoo RK
BMC Cancer; 2021 May; 21(1):630. PubMed ID: 34049505
[TBL] [Abstract][Full Text] [Related]
17. Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.
Machida N; Yoshino T; Boku N; Hironaka S; Onozawa Y; Fukutomi A; Yamazaki K; Yasui H; Taku K; Asaka M
Jpn J Clin Oncol; 2008 Oct; 38(10):689-94. PubMed ID: 18845522
[TBL] [Abstract][Full Text] [Related]
18. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.
Schrock AB; Ouyang C; Sandhu J; Sokol E; Jin D; Ross JS; Miller VA; Lim D; Amanam I; Chao J; Catenacci D; Cho M; Braiteh F; Klempner SJ; Ali SM; Fakih M
Ann Oncol; 2019 Jul; 30(7):1096-1103. PubMed ID: 31038663
[TBL] [Abstract][Full Text] [Related]
19. Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma.
Korphaisarn K; Morris V; Davis JS; Overman MJ; Fogelman DR; Kee BK; Dasari A; Raghav KPS; Shureiqi I; Trupti M; Wolff RA; Eng C; Menter DG; Hamilton S; Kopetz S
Br J Cancer; 2019 Sep; 121(6):505-510. PubMed ID: 31406299
[TBL] [Abstract][Full Text] [Related]
20. Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status.
Modest DP; Stintzing S; Laubender RP; Neumann J; Jung A; Giessen C; Haas M; Aubele P; Schulz C; Boeck S; Stemmler HJ; Kirchner T; Heinemann V
Anticancer Drugs; 2011 Oct; 22(9):913-8. PubMed ID: 21795973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]